Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.
The schedule of presentations from Infinity's anti-cancer programs is as follows:
| Saturday, June 5, 2010: 2:00 – 6:00 p.m. CDT |
| Poster Session Title: Hedgehog pathway inhibition impedes ovarian cancer xenograft growth in the adjuvant and maintenance settings |
| Presenter: Bo Rueda, Ph.D., Associate Professor, Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School and Associate Director, Vincent Center for Reproductive Biology, Massachusetts General Hospital |
| Location: S Hall A2 |
| |
| Sunday, June 6, 2010: 8:00 a.m. – 12:00 p.m. CDT |
| Poster Session Title: Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC) |
| Presenter: Antonio Jimeno, M.D., Ph.D., Associate Professor, Division of Medical Oncology and Director, Head and Neck Cancer Medical Oncology Program and Developmental Therapeutics/Pharmacodynamics Laboratory, University of Colorado Denver School of Medicine |
| Location: S Hall A2 |
| |
| Monday, June 7, 2010: 3:00 – 5:30 p.m. CDT |
| Poster Session Title: Association between Anaplastic Lymphoma Kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC) |
| Presenter: Lecia V. Sequist, M.D., M.P.H., of Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine, Harvard Medical School |
| Location: E Hall D2 |
Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases